Company Release
12.30 Finnish time / 11.30 Swedish time
Disclosure of
Nanoform has one series of shares in which each share carries one vote. The percentage numbers indicate the shareholding on the date the Act entered into force on
Total positions of Edward Hæggström subject to the notification obligation: | ||||
% of shares and voting rights (total of 7.A) |
% of shares and voting rights through financial instruments (total of 7.B) | Total of both in % (7.A + 7.B) |
Total number of shares and voting rights of issue (on | |
Resulting situation on the date on which threshold was crossed or reached | 6,90% | 0,08% | 6,98% | 78,445,164 |
Position of previous notification (if applicable) | - | - | - |
Notified details of the resulting situation on the date on which the threshold was crossed or reached: | ||||
A: Shares and voting rights | ||||
Class/type of sharesISIN code (if possible) | Number of shares and voting rights | % of shares and voting rights | ||
Direct(SMA 9:5) | Indirect(SMA 9:6 and 9:7) | Direct(SMA 9:5) | Indirect(SMA 9:6 and 9:7) | |
FI4000330972 | 5,409,405 | - | 6,90% | - |
- | - | - | - | - |
- | - | - | - | - |
SUBTOTAL A | 5,409,405 | 6,90% |
B: Financial Instruments according to SMA 9:6a | |||||
Type of financial instrument | Expiration date | Exercise / Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
Stock option |
Until | Physical settlement | 59,774 | 0,08 | |
- | - | - | - | - | - |
- | - | - | - | - | - |
SUBTOTAL B | 59,774 | 0,08 |
Information in relation to the person subject to the notification obligation ☒ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.☐ Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity: | |||
% of shares and voting rights | % of shares and voting rights through financial instruments | Total of both | |
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
The notification of major shareholdings is based on the law 163/2024, in accordance with which a shareholder of a First North company is required to notify certain major shareholdings within two months from the entry into force of the law, in the event that the holding of shares or votes on the entry into force of the law on
For further information, please contact:
peter.hanninen@nanoform.com, +358 50 353 0408
For investor relations queries, please contact:
hvh@nanoform.com, +46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
https://news.cision.com/nanoform/r/disclosure-of-major-holdings-under-law-163-2024,c3990724
https://mb.cision.com/Main/18905/3990724/2830575.pdf
(c) 2024 Cision. All rights reserved., source